Clinical trial
A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer
NCT00813163 is registered in ClinicalTrials.gov with PharmaEngine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer
- Lead sponsor
- PharmaEngine
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- July 31, 2012
- Enrollment
- 41 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.